Arena Pharmaceuticals' (ARNA) Lorcaserin Proposed for DEA Schedule IV - InvestingChannel

Arena Pharmaceuticals’ (ARNA) Lorcaserin Proposed for DEA Schedule IV

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

Top NewsMost Read Highlighted

Get AlertsARNA Hot Sheet

NEUTRAL ( Down)

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is seeing activity after its Lorcaserin was proposed for DEA Schedule IV placement. Link

The Drug Enforcement Administration (DEA) proposes placing the substance lorcaserin, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into Schedule IV of the Controlled Substances Act (CSA).

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW

Related posts

OCZ Technology (OCZ) Concludes Investigation, Will Restate Certain Qtr. Results

Street Insider

Google Maps: 10 Million Downloads In 48 Hours

ValueWalk

Award-Winning Journalist Jason Kobely Joins CraveOnline Media, #1 Male Lifestyle Publisher on the Web

Street Insider

Quanex (NX) to Acquire Alumco

Street Insider

Sirius XM Radio (SIRI) Gets A Positive Boost From CRB: BAML

ValueWalk

Boeing, Embraer Announces Collaboration for Improved Runway Safety

Benzinga.com